The Cooper Companies, Inc. (COO) $70.70
Cooper Companies is testing a critical technical ceiling, and the current setup suggests the risk-reward ratio is skewed to the downside.
52-wk High $89.83
📌 Investment Snapshot
- Trading at $70.70 with a demanding 59.9x P/E multiple.
- Latest quarter reported $1.08B in revenue and a $0.40 EPS loss.
- Technical confluence score hits 100/100, yet RSI 65.4 signals overbought conditions.
- Consensus target of $81.07 implies 14.6% upside potential.
COO faces stiff resistance near the $71-$72 level, where multiple bearish Fair Value Gaps (FVGs) remain unfilled. The stock’s proximity to these zones, combined with an RSI of 65.4, makes a near-term pullback highly probable.
| 📍 Entry Zone | $64.00 or below | 🛑 Stop-Loss | $58.50 |
| 📋 Adjust If | A clean breakout above $72.00 on high volume would invalidate the bearish thesis. | ||
The Investment Case — Why Now?
The Cooper Companies finds itself in a precarious spot. While the firm maintains a dominant position in the contact lens and women’s healthcare markets, the recent earnings volatility—specifically the $0.40 loss in the April quarter—has tempered institutional enthusiasm. The current valuation of nearly 60x earnings requires flawless execution, which the recent financials have yet to deliver.
Liquidity sweeps at $72.15 indicate institutional sellers are active near current levels, capping upside momentum. With the stock trading well below its 200-day moving average of $72.89, the path of least resistance remains lower until the bulls can reclaim this key structural level. Does the current premium valuation justify the earnings volatility we witnessed last quarter?
🤔 Does the current premium valuation justify the earnings volatility we witnessed last quarter?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
📈 Price Action & Technicals
Inside VA
Sell-side Sweep at $72.15 on 2026-07-06
COO is currently wrestling with the 50-day moving average of $64.91, having cleared it recently, but it remains trapped below the critical 200-day SMA of $72.89. This positioning defines a classic ‘no-man’s land’ where the stock lacks the conviction to break out or the weakness to collapse immediately.
The RSI at 65.4 signals that the recent rally is losing steam, and the ADX reading of 40.9 confirms a strong trend is in place—but the sell-side liquidity sweep at $72.15 suggests that trend may be facing exhaustion. Traders should watch the bearish FVG zones between $71.09 and $71.84, as these areas act as magnets for supply.
The Volume Profile Point of Control (POC) sits significantly higher at $81.79, indicating that a large volume of historical trading occurred well above current prices. This creates a ‘gravity’ effect where the stock struggles to sustain rallies without significant buying volume, which is currently absent (volume ratio 0.46x).
The Anchored VWAP from May 11th at $65.76 serves as the primary support level. Any breach below this price would likely trigger a retest of the $60.64 liquidity sweep zone, invalidating the current bullish short-term structure.
Ultimately, the confluence of unfilled bearish FVGs and overbought RSI readings warns against chasing the stock at $70.70. Patience is the prudent strategy here. How would you adjust your position if the stock fails to clear the $72.00 resistance level by next week?
🤔 How would you adjust your position if the stock fails to clear the $72.00 resistance level by next week?
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| COO | The Cooper Companies | 59.9x |
| SPY | S&P 500 | 22.5x |
| ALGN | Align Technology | 35.2x |
| DHR | Danaher | 32.1x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q2 2026 | $1.08B | -$0.40 | N/A |
| Q1 2026 | $1.02B | $0.66 | N/A |
| Q4 2025 | $1.06B | $0.42 | N/A |
| Q3 2025 | $1.06B | $0.49 | N/A |
Free cash flow remains tight at $0.1B for the latest quarter, limiting the company’s ability to engage in aggressive buybacks or M&A activity.
The erratic EPS performance, swinging from positive to negative, underscores operational challenges that the market has yet to fully price in.
🚀 Growth Drivers — What Moves the Stock
- Contact Lens Demand 🟡 Priced In — Steady recurring revenue from daily disposables provides a defensive moat.
- Women’s Healthcare Expansion 🟢 Upside Surprise — Strategic focus on fertility and surgical solutions offers long-term growth potential.
🤔 Do you believe the company’s focus on women’s healthcare can offset the volatility in the core contact lens business?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Blackrock Inc. | 16,618 |
| Vanguard Capital Management | 12,718 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| WEISS ROBERT S | Director | 2026-04-01 | Purchase | 3654 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 4.3% | 1.9 |
⚠ Key Risk Factors
~$2B impact
~$0.5B impact
🤔 Which risk factor concerns you more: the high valuation or the sensitivity to interest rates?
🎯 Guidance & Wall Street View
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $92.00 | $81.07 | $66.00 | 14 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Citigroup | Neutral | $N/A | 2026-07-08 | main |
| Stifel | Buy | $N/A | 2026-06-05 | main |
Analysts remain broadly optimistic, yet recent downgrades to Neutral suggest caution is creeping into the consensus view.
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Strong market share in contact lenses.
- Potential for margin expansion in women’s health.
📊 Base Case
The stock continues to trade in a range, constrained by resistance at $72 and support at $65.
🐻 Bear Case
- High P/E multiple vulnerable to earnings volatility.
- Unfilled bearish FVGs overhead.
🎯 Investor Action Plan — By Profile
Avoid new longs until the stock clears $72.00 on volume or pulls back to the $64-$65 support zone.
The current valuation is too rich. Wait for a better entry point closer to the $60 support level.
Maintain existing positions but avoid adding at current levels given the overbought RSI.
❓ Investor FAQ — People Also Ask
Q: Why is the P/E ratio so high?
The high multiple reflects market expectations for future growth in the women’s healthcare segment, despite recent earnings volatility.
Q: What is the most critical level to watch?
$72.00 is the key resistance level; a breakout here would change the technical outlook to bullish.
Q: Is the stock overbought?
With an RSI of 65.4, the stock is approaching overbought territory, signaling that a near-term pullback is likely.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 How has the stock moved since this analysis?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. All investments carry risk.
All active positions and their real-time performance are tracked on our Investment Log.
#COO #CooperCompanies #Healthcare #StockMarket #Investing #WallStreet #TechnicalAnalysis #Earnings